Authors: LEROUX Y GUIMART C TENENHAUS M

Citation: Y. Leroux et al., USE OF THE REPEATED CROSS-OVER DESIGN IN ASSESSING BIOEQUIVALENCE - (WITHIN AND BETWEEN SUBJECTS VARIABILITY - SCHUIRMANN CONFIDENCE-INTERVALS ESTIMATION), European journal of drug metabolism and pharmacokinetics, 23(2), 1998, pp. 339-345

Authors: FRYDMAN A COLLIGNON F OZOUX ML SPIRO T ROMARY MC GUIMART C LEROUX Y

Citation: A. Frydman et al., A POPULATION APPROACH TO ENOXAPARIN DISPOSITION PROFILE IN A MULTICENTER CLINICAL-TRIAL INVOLVING TOTAL KNEE REPLACEMENT PATIENTS GIVEN SUBCUTANEOUSLY THE 30-MG BID DOSE REGIMEN, Thrombosis and haemostasis, 73(6), 1995, pp. 971-971

Authors: MONTAY G BRUNO R VERGNIOL JC EBMEIER M LEROUX Y GUIMART C FRYDMAN A CHASSARD D THEBAULT J

Citation: G. Montay et al., PHARMACOKINETICS OF SPARFLOXACIN IN HUMANS AFTER SINGLE ORAL-ADMINISTRATION AT DOSES OF 200-MG, 400-MG, 600-MG, AND 800-MG, Journal of clinical pharmacology, 34(11), 1994, pp. 1071-1076

Authors: FILLASTRE JP MONTAY G BRUNO R ETIENNE I DHIB M VIVIER N LEROUX Y GUIMART C GAY G SCHOTT D

Citation: Jp. Fillastre et al., PHARMACOKINETICS OF SPARFLOXACIN IN PATIENTS WITH RENAL IMPAIRMENT, Antimicrobial agents and chemotherapy, 38(4), 1994, pp. 733-737